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1. Data {#sec1}
=======

In this Data in Brief article, we provide the baseline characteristics of the total glucose intolerance, obesity and hypertension (GOH) Israel cohort [@bib2] and Phase-3 CVD incidence for the active follow-up subsample ([Table 1](#tbl1){ref-type="table"}). We describe the incidental ECG abnormalities frequencies of the cohort at baseline ([Table 2](#tbl2){ref-type="table"}) and summarize the CVD and all-cause mortality according to normal vs. abnormal ECG status ([Table 3](#tbl3){ref-type="table"}). The statistical methods for assesing the performance measures of the CVD and all-cause mortality risk prediction models are detailed in 2.1, followed by a summary of these measures ([Table 4](#tbl4){ref-type="table"}). The full data of the Net Reclassification Improvement (NRI) following the addition of ECG incidental findings to CVD risk prediction models is also presented ([Table 5](#tbl5){ref-type="table"}).Table 1Baseline characteristics of the total glucose intolerance, obesity and hypertension (GOH) Israel cohort and Phase 3 CVD incidence active follow-up subsample.Table 1Total cohort (N = 2601) N (%)CVD follow-up group (N = 930) N (%)P. valueSex Male1267 (48.7)465 (50.0)0.45 Female1334 (51.3)465 (50.0)Age Years (Mean ± SD)52.6 ± 8.149.0 ± 6.9\<0.001Year of birth 1912--1921763 (29.3)113 (11.7)\<0.001 1922--1931963 (37.0)362 (37.5)0.769 1932--1941875 (33.6)491 (50.8)\<0.001Origin Yemen648 (24.9)200 (21.5)0.037 Middle-East/Asia652 (25.1)255 (27.4)0.166 North Africa528 (20.3)156 (16.8)0.020 Europe/America773 (29.7)319 (34.3)0.009Smoking Never1573 (60.5)577 (62.0)0.342 Former smoker166 (6.4)62 (6.7) Current smoker860 (33.1)291 (31.3)BMI (Kg/M^2^) Mean (±SD)26.2 ± 4.325.7 ± 3.7\<0.001 Normal1087 (42.3)282 (30.6)\<0.001 Overweight1060 (41.3)431 (46.7)0.005 Obese421 (16.4)210 (22.8)\<0.001Blood pressure (mmHg) Systolic (Mean ± SD)132.8 ± 22.0126.3 ± 18.6\<0.001 Diastolic (Mean ± SD)84.4 ± 11.582.8 ± 11.0\<0.001 Normal728 (28.4)359 (38.9)\<0.001 Pre-hypertension880 (34.3)309 (33.5)0.675 Hypertension957 (37.3)254 (27.5)\<0.001Total Cholesterol (mg/dL) Mean (±SD)219.8 ± 54.0217.5 ± 52.80.119 Normal697 (39.4)303 (40.2) Borderline446 (25.2)202 (26.8)0.141 High risk627 (35.4)248 (32.9)Creatinine (mg/dL) Mean (±SD)0.96 ± 0.30.97 ± 0.40.763Blood glucose Normoglycemia933 (36.1)309 (33.2)0.132 Pre-diabetes1294 (50.0)465 (50.0)1.000 Diabetes361 (13.9)155 (16.7)0.041[^1][^2][^3][^4]Table 2ECG abnormal findings according to the Minnesota classification [@bib3] and frequencies (n) in the glucose intolerance, obesity and hypertension (GOH) Phase-2 cohort at baseline.Table 2Single chamber pacemaker (0)Clockwise rotation (20)Drug effect (8)Dual chamber pacemaker (0)Non-specific T wave changes (II, III, AVF) (284)Atrial fibrillation (8)Single SVPB (45)Non-specific ST-segment changes (II, III, AVF) (277)Atrial flutter (0)Multiple SVPB (22)Non-specific T wave changes (I, AVL, V5-V6) (335)Atrial tachycardia (1)Single VPB (45)Non-specific ST-segment changes (I, AVL, V5-V6) (218)Diastolic overload (0)Multiple VPB (26)Non-specific T wave changes (V1-V4) (200)Complete left BBB (8)Low voltage (51)Non-specific ST-segment changes (V1-V4) (84)Complete right BBB (29)Mitral P wave (55)J point elevation (139)Intermittent right BBB (1)Pulmonary P wave (36)Terminal T negativity (3)Intermittent left BBB (0)First degree AV block (51)Tall T waves (32)Past MI (0)Short PR (9)Prolonged QT (23)Past MI suspicion (108)- elaborate the followingsLeft-axis (\<-30°) (168)Left ventricular hypertrophy (159)Diaphragmatic (62)Right axis (\>90°) (35)Right ventricular hypertrophy (6)Anteroseptal (32)Incomplete right BBB (114)Myocardial Ischemia (46)- elaborate the followingsAnterolateral (6)Incomplete left BBB (21)Diaphragmatic wall (8)Anterior (0)Intraventricular conduction delay (QRS\>0.11) (188)Anterior wall (21)Lateral (3)V1- RSR′ pattern (32)Lateral wall (16)High lateral (4)WPW (2)Posterior wall (1)True posterior (1)Poor R wave progression (64)Left ventricular strain (43)Subendocardial ischemia (0)Counterclockwise rotation (330)Persistent ST-segment elevation (0)Other (471)[^5][^6][^7]Table 3CVD 23-year cumulative incidence and 31-year all-cause mortality among individuals with normal ECG tests and those with incidental abnormal ECG findings during Phase-2 GOH data collection.Table 3Total N (%)ECG testP valueAbnormal ECG findings n (%)Normal ECG n (%)CVD incidenceCVD294 (31.6)141 (38.5)153 (27.1)\<0.001No- CVD636 (68.4)225 (61.5)411 (72.9)All-cause mortalityDead1719 (66.1)910 (75.9)809 (57.7)\<0.001Alive882 (33.9)289 (24.1)593 (42.3)Table 4Summary of performance measures for models of 23-year CVD-risk and 31-year all-cause mortality risk prediction.Table 4CVDAll-cause mortalityTraditional risk factors (95% CI)Traditional risk factors + ECG % (95% CI)p. valueTraditional risk factors (95% CI)Traditional risk factors + ECG % (95% CI)p. valueNRI[a](#tbl4fna){ref-type="table-fn"}7.4 (1.5--13.3)0.01[a](#tbl4fna){ref-type="table-fn"}0.6 (−1.3--2.6)0.52Continuous NRI[a](#tbl4fna){ref-type="table-fn"}25.8 (12.0--39.5)\<0.01[a](#tbl4fna){ref-type="table-fn"}41.0 (33.1--48.9)\<0.01IDI[a](#tbl4fna){ref-type="table-fn"}0.63 (0.08--1.17)0.02[a](#tbl4fna){ref-type="table-fn"}0.21 (0.04--0.39)0.02C-index0.656 (0.619--0.694)0.666 (0.629--0.703)0.140.752 (0.751--0.753)0.753 (0.752--0.754)[b](#tbl4fnb){ref-type="table-fn"}[^8][^9][^10]Table 5Predicted 23-year CVD risk probabilities of 916 seemingly healthy men and women by a multivariable model[a](#tbl5fna){ref-type="table-fn"}, with and without ECG findings.Table 5Model without ECGModel with ECGTotalCorrectly reclassifiedPredicted CVD risk[b](#tbl5fnb){ref-type="table-fn"}Low \<20%Intermediate 20 - \<30%High ≥30%**Participants who experienced a CVD event** n (%)\<20%18 (6.2)7 (2.4)0 (0.0)2520 - \< 30%8 (2.8)52 (18.0)17 (5.9)77≥30%0 (0.0)14 (4.8)173 (59.9)187Total26731902890.69%**Participants who did not experience a CVD event** n (%)\<20%115 (18.3)22 (3.5)0 (0.0)13720 - \< 30%42 (6.7)135 (21.5)29 (4.6)206≥30%0 (0.0)51 (8.1)233 (37.2)284Total1572082626276.7%[^11][^12][^13][^14]

[Fig. 1](#fig1){ref-type="fig"} shows the ROC curves of CVD risk prediction with vs. without ECG incidental findings. [Fig. 2](#fig2){ref-type="fig"} present the All-cause mortality risk prediction Cox model calibration curve.Fig. 1ROC curves of CVD prediction models comprising traditional CVD risk factors[1](#fn1){ref-type="fn"}, including (blue line) and not including (red line) ECG testing.Fig. 1Fig. 2All-cause mortality risk prediction Cox regression model calibration curve.Fig. 2

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Assessment of performance measures for CVD and all-cause mortality risk prediction models - statistical methods {#sec2.1}
--------------------------------------------------------------------------------------------------------------------

To evaluate discrimination improvement, we compared the C-index of the prediction model with traditional CVD risk factors and a model with additional ECG findings. The C-index for the CVD prediction model by logistic regression was calculated by the area under the receiver operating characteristic curve, whereas the C-index for all-cause mortality prediction was calculated by C-index adaption for Cox proportional hazard regression, as proposed by Harrell et al. [@bib4], with the confidence interval calculated by bootstrap resampling with 200 repetitions. We assessed net reclassification improvement (NRI) when incidental ECG findings are added to traditional CVD risk factors at individual risk stratification. The NRI was estimated as described by Pencina et al. [@bib5]:$$NRI = {\lbrack\frac{(\text{number}\ \text{of}\ \text{events}\ \text{reclassified}\ \text{higher} - \text{number}\ \text{of}\ \text{events}\ \text{reclassified}\ \text{lower})}{\text{number}\ \text{of}\ \text{events}} - \frac{(\text{number}\ \text{of}\ \text{non} - \text{events}\ \text{reclassified}\ \text{higher} - \text{number}\ \text{of}\ \text{non} - \text{events}\ \text{reclassified}\ \text{lower})}{\text{number}\ \text{of}\ \text{non} - \text{events}}\rbrack}$$

For this purpose, we defined cutoffs for the likelihood to reach the outcome of interest, by adjusting the ACC/AHA [@bib6] risk categories (low, intermediate and high risk) to the increased duration of follow-up, from 10% to 20%--20% and 30%, similar to the Framingham study extension method [@bib7]. We estimated the improvement in reclassification also by continuous NRI measure and the integrated discrimination index (IDI), which are not affected by the chosen cutoff values, in contrast to the NRI measure. Continuous NRI relies on the proportion of individuals with outcome correctly assigned a higher probability and individuals without outcome correctly assigned lower probability, by the new model. IDI reflects the average increase in predicted risk among cases plus the analogous average decrease among controls [@bib5].

Calibration curve of 2520 model 2 participants in all-cause death multivariable analysis. Bootstrap resampling with 200 repetitions for 30-year survival prediction.
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ROC curves of a logistic regression model with the covariates: sex, age, origin, blood pressure, BMI and smoking status (model 3). AUC of 0.666 (0.629--0.703), including ECG testing (blue line) vs AUC of 0.656 (0.619--0.694), without ECG testing (red line), p = 0.14.

[^1]: • Blood pressure classification: Normal-systolic BP ≤ 120 and diastolic BP ≤ 80; Prehypertension- 140 \> systolic BP ≥ 120 or 90 \> diastolic BP ≥ 80; Hypertension - systolic BP ≥ 140 or diastolic BP ≥ 90.

[^2]: • Total cholesterol classification: Normal- Total cholesterol \<200; Borderline- 200 ≤ Total cholesterol \<240; High risk ≥240.

[^3]: • BMI classification: Normal- BMI \<25; Overweight- 25 ≤ BMI \<30; Obese- BMI ≥30.

[^4]: • Diabetes defined if any of the following criteria were fulfilled: FPG ≥126 mg/dL (100--125 mg/dL = prediabetes), OGTT ≥200 mg/dL (140--199 mg/dL = prediabetes), self-report of diabetes or treatment with anti-diabetic drugs.

[^5]: • SVBP- Supraventricular premature beats; VPB- Ventricular premature beats; AV block- Atrioventricular block; BBB- Bundle branch block; WPW- Wolff--Parkinson--White; MI- Myocardial infarction.

[^6]: • More than one finding was recorded for some individuals.

[^7]: • Individuals with the following findings were excluded: Single chamber pacemaker, dual chamber pacemaker and past MI.

[^8]: CVD = cardiovascular disease, NRI = Net Reclassification Index, IDI = Integrated Discrimination Index.

[^9]: Net reclassification improvement is calculated for a model with the addition of ECG findings as compared to a model with traditional risk factors only.

[^10]: Comparison of Harrel\'s C indices for Cox models has unclear reliability [@bib8], thus we calculated 95%CI by bootstrapping (200 repetitions) method and demonstrated a statistically insignificant improvement by confidence intervals overlap.

[^11]: Abbreviations: CVD-cardiovascular disease; ECG- Electrocardiogram.

[^12]: Net Reclassification Improvement (NRI): Overall - 7.39% (95% CI, 1.48%--13.3%, p = 0.014) non-events correctly reclassified (nonevent NRI) - 6.70% events correctly reclassified (events NRI) - 0.69%. Continuous NRI = 25.75% (12.01%--39.50%, p \< 0.001), Identification Discrimination Improvement (IDI) = 0.63% (p = 0.024).

[^13]: The model is adjusted for: age, sex, origin, BMI, blood pressure, diabetes and smoking status (Model 2).

[^14]: Levels of risk are based on ACC/AHA ASCVD Risk thresholds [@bib6] with adjustment to the increased duration of follow-up, similar to Pencina et al. approach [@bib7].
